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Discovery of a CHEK2 mutation in cancer patients necessitates discussion about the risk for 
additional tumors and screening to reduce morbidity and mortality from other concurrent CHEK2 
mutation-related cancers. Rectal neuroendocrine tumors (NETs), formerly called carcinoids, are 
relatively rare, representing less than 1% of rectal cancers.1,2  While the CHEK2 mutation is 
associated with adenocarcinoma of the colon, it has not been identified in association with NETs, 
and, to our knowledge, there is only one other case of an appendiceal NET in a patient with 
CHEK2 mutation.3 We report a patient who had ductal carcinoma in situ (DCIS) breast cancer 




A 67-year-old Caucasian female with a history of estrogen receptor-positive DCIS breast cancer 
had genetic testing with a panel of 28 actionable genes, including BRCA1 and BRCA2, as the 
result of a strong family history (her grandmother and sister) of breast cancer. The patient was 
found to have a germline c1100 del CHEK2 mutation. Because of the association of CHEK2 
mutation with colorectal adenocarcinoma, she underwent colonoscopy. This was her first 
colonoscopy as previously, she had refused this procedure, opting instead for occult blood testing 
as a colorectal cancer screening. Upon colonoscopy, a polyp of less than 1 cm in diameter was 
discovered in the rectum. Pathology showed that the tumor was characterized by a submucosal 
neoplastic proliferation of cytologically bland, mitotically inactive cells arranged in cords and 
nests. The cells stained strongly positive for CD56, synaptophysin, and the cytokeratin cocktail 
AE1/AE3, which are markers classically associated with NETs (Figures 1-3). Patient consent 
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Figure 1. Low-power hematoxylin and eosin-stained image of the colonic mucosa with loss of 
the normal test tube appearance of colonic crypts due to distortion by the neoplasm. 100x 
magnification. The arrows indicate a normal crypt. 
 
 
Figure 2. High-power hematoxylin and eosin-stained image of the neoplastic cells within the 




Figure 3. High-power image of the neoplastic cells stained with antibodies directed against 
synaptophysin, a marker of neuroendocrine differentiation. Normal colonic crypt is indicated by 
the arrow. 200x magnification. 
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The rectal tumor was completely removed by polypectomy during colonoscopy, and the location 
was subsequently tattooed to mark the tumor site. Surveillance for recurrence after 2 and 6 




CHEK2 germline mutation is known to be associated with adenocarcinomas of the breast and 
colon, but only one other case of NET associated with this mutation has been reported.3 Some 
providers offer next-generation genetic screening to all cancer patients without limitation by 
insurance or finances in order to develop a genetic registry.3 One such group uncovered six cases 
of NETs associated with different cancer-predisposing genes, including APC, MUTYH, MSH-6, 
MLH1, and CHEK2. Only one of the six patients harbored a CHEK2 mutation. This patient had 
an appendiceal goblet cell tumor, and immunohistochemical staining yielded a diagnosis of NET. 
 
Gastrointestinal NETs are the most common type (43%), and rectal location NETs account for 
only 15% of the gastrointestinal NETs. The second most common location for NETs is the lung, 
representing 31.9% of NET cases reported.4 Rectal and anal NETs with diameters of less than 1 
cm have the best prognosis, so early detection is important.5 We realize this report will not 
change practice, because we already perform colonoscopy on patients with CHEK2 mutation to 
look for adenocarcinoma; however, confirmation of the association of CHEK2 mutation with 
NETs may lead to trials of screening other parts of the body, such as the lung, for early detection 
and reduction of cancer mortality. 
 
The CHEK2 gene codes for a protein that acts as a tumor suppressor, regulating excessive cell 
growth. In response to damage in the cell, CHEK2 communicates with other well-known 
regulators of mitosis as well such as tumor protein 53 (tp53).6 It is not surprising that a mutation 
that limits the action of CHEK2 results in tumor growth because the role of CHEK2 is to limit 
unwarranted proliferation.7 
 
As more genetic testing is performed, we will likely identify additional tumors that are 
associated with CHEK2 mutation. For example, a 48-year-old female patient with the CHEK2 
mutation was found to have adrenocortical carcinoma.8 Surveillance testing discovered an 
adenocarcinoma in her left lower lung 2 months later. Additionally, a population-based study 
revealed an increased risk of breast cancer, stomach cancer, kidney cancer, sarcoma, and prostate 
cancer in patients with CHEK2 mutations.9 The NIH website reference to CHEK2 links this gene 




This study provides new information about CHEK2 mutation in association with a rectal NET, 
adding to the growing body of knowledge about this mutation. While CHEK2 mutations are 
associated with colonic adenocarcinomas, to our knowledge only one other reported case of 
CHEK2 mutation in association with a gastrointestinal NET has been reported. Greater 
knowledge of these associations may potentially lead to earlier diagnosis of cancer in patients 
with CHEK2 mutation, due to increased preventive screening in these high-risk patients. As 
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more genetic testing is performed, we suspect there will be reports of additional cancers 
associated with CHEK2 mutation. 
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